Designing a Defensible Clinical Study with an AI Co-Pilot

I designed the M2 OPERA pilot and the ARM2 meta-analysis using this workflow. AI helped at every stage — but the judgment call that makes a study defensible to reviewers, IRBs, and editors never transferred to the model. That distinction matters more than most tutorials admit.

Why AI Speeds Up the Wrong Things

The default AI use in study design is generating an outline. That's the least valuable stage to outsource. The decisions that determine whether your study can actually answer the question happen in PICO framing, design selection, and randomization scheme. Rush those with AI and you get a well-formatted protocol with a fundamental flaw buried inside it.

The six stages below put AI where it earns its keep. Each names the prompt and the human check that can't be automated away.

Stage 1: PICO Sharpening

Feed the model your rough research question and ask it to enumerate every plausible PICO interpretation — population strata, outcome timing, comparator options, feasible follow-up durations. Don't ask it to pick one. Ask it to surface the decision space.

The human check: you select the PICO that matches your patient population, available data, and institutional capacity. The model expands the possibility space; you constrain it to what's real. This is the stage where clinical researchers are often too narrow too early — and where AI is genuinely useful as a structured prompt for scope.

Stage 2: Design Fit

Once PICO is fixed, prompt: "Given this PICO, list the study designs that could answer it, with the main assumption each design requires and the sample size implications." Claude handles common designs well — RCT, cohort, case-control, diagnostic accuracy. It underperforms on adaptive designs and platform trials.

The human check: does your context satisfy the design's core assumptions? A cluster RCT requires an ICC estimate your pilot may not have produced. Claude won't flag that gap unless you explicitly tell it the gap exists.

For red-teaming the chosen design itself — finding the holes in your protocol before reviewers do — red-teaming study design with Claude covers that systematically.

Stage 3: Sample Size

Feed the model the design narrative — not the formula — and ask it to name the statistical test, enumerate the inputs required for a power calculation, and then calculate. The failure pattern: Claude defaults to simple parallel-arm formulas and routinely misses inflation factors for clustering, non-inferiority margins, and expected dropout.

The human check: confirm the test family matches your design before accepting any numbers. If you're running a cluster trial and Claude doesn't mention ICC inflation, the calculation is wrong. A 10-minute human check here is cheaper than an underpowered study.

Stage 4: Randomization

Generate randomization code with AI, then audit three things manually: allocation concealment (can the enroller access the sequence?), stratification (does your design require balancing on a covariate?), and audit trail (who holds the schedule and when is it revealed?). I've reviewed LLM-generated R scripts for colleagues where the block size was fixed and predictable — allocation concealment silently broken.

Read the generated code before running it. Every time.

Stage 5: Reporting Standard

Ask the model to identify the relevant reporting guideline for your design (CONSORT, STROBE, STARD, PRISMA-DTA) and generate a fillable checklist. Fill it out now, before you start wrting. This surfaces any sections your design doesn't yet address — gaps you can close prospectively, before they become reviewer comments.

Reporting compliance is close to mechanical. The model handles it well; use it at this stage without hesitation. The research workflow on choosing a study design goes deeper on design taxonomy if you need to revisit the classification before this step.

Stage 6: Pre-Registration

Draft the OSF pre-registration with AI assist, but treat the analysis plan as the protected step. Over-specification locks you into subgroup tests you weren't powered to run. Under-specification gives reviewers ammunition to dismiss your results as exploratory.

Prompt: "Draft an OSF analysis plan for this design. Flag anywhere you're making assumptions I haven't confirmed." Then push back on every flagged assumption before registering. Register before data collection — that part isn't negotiable and AI can't make the decision for you.

What AI Commonly Gets Wrong

The biggest trap is not a dramatic hallucination. It is a plausible-looking default that slides in because the model is trying to be helpful. In study design, that usually means one of four things: the population is too broad, the comparator is too weak, the outcome is too vague, or the analysis plan assumes more precision than the data can support.

If you ask a model to "design a study on postoperative pain," it will happily give you something readable. It will not force you to decide whether the population is neonates, school-age children, or adolescents; whether the relevant endpoint is VAS at 6 hours or opioid consumption over 48 hours; or whether the study should be superiority, non-inferiority, or feasibility. Those are not wording problems. They are design problems. AI can help you enumerate them, but it cannot rank them against your actual constraints unless you make those constraints explicit.

The same is true for statistics. LLMs are good at algebra once the assumptions are fixed. They are weaker at deciding whether the assumptions are the right ones. If your model output says "t-test," "chi-square," or "simple regression" without naming the design context, treat that as a warning, not a shortcut. A clean-looking analysis that is mismatched to the design is worse than no analysis at all, because it creates false confidence.

A Practical Prompt Stack

You do not need one giant prompt. You need a sequence that narrows the design step by step:

1. "Here is the rough clinical question. Give me every plausible PICO version and tell me what would change for each."
2. "Given these PICO options, list the study designs that could answer them and what assumption each one depends on."
3. "For the selected design, list the minimum data elements, the primary outcome, likely confounders, and the first-pass sample size logic."
4. "Generate a draft protocol skeleton, but flag any section where you are assuming missing information."
5. "Create a checklist of human review points that must be signed off before registration."

That sequence matters because it forces the model to stay in the role of a structured assistant rather than a pseudo-authority. It also makes the human edits easier. You are not correcting a finished draft line by line. You are intervening at the exact point where the model overreaches.

In practice, I find the best use of AI is to ask for the adjacent alternative before committing to a choice. If the model gives you one design, ask for the next-best design and why it loses. If it gives you one outcome definition, ask for the most defensible alternate definition and the tradeoff. That comparative framing surfaces hidden assumptions fast.

When Not to Use AI

There are parts of protocol writing where AI is simply the wrong tool. Institutional feasibility, ethics, and local workflow constraints are not generic writing problems. If the answer depends on your IRB norms, data access rules, or who actually enters the operating room schedule, you need a human answer from your site. No model can replace that.

The other hard no is anything that requires domain judgment about harm. If a protocol choice changes exposure risk, consent burden, or the possibility of misleading inference, the model should not be the final arbiter. Use it to structure the options, not to bless the decision.

That boundary is what makes the workflow defensible. Reviewers do not object because AI was used. They object when the manuscript cannot show where the human judgment happened. If you can point to the exact stage where you narrowed scope, rejected a convenient design, or corrected a statistical default, the role of AI becomes transparent rather than suspect.

The Real Payoff

The practical payoff of this workflow is not speed alone. Speed is useful, but the bigger win is that it keeps the design conversation in the open. A protocol usually fails when one critical assumption stays implicit for too long. AI is useful because it forces the assumption to appear on the page.

That is why I like using it before a draft becomes too polished. Once a protocol looks complete, teams become reluctant to change it. Early AI-assisted critique keeps the document malleable long enough for the hard questions to get answered. By the time you register or submit, the boring parts should be boring because the interesting parts were already argued through.

If you want the short version, it is this: let AI generate the candidate structure, let the clinician choose the constraints, and let the statistician verify the consequences. That division of labor is what makes the study defensible.

One final rule: if the model starts sounding certain before you are certain, slow down. Confidence is not evidence. In protocol work, the useful AI output is the one that makes uncertainty visible early enough to act on it. That is the point at which the tool stops being a drafting toy and starts being a real co-pilot.

---

The Research Mentor tools at aiforacademic.world — Validate idea and Generate outline (PICO) — cover stages 1 and 2 in a single Workspace session, chaining PICO sharpening to outline generation without losing context between steps. If you're working through this workflow under time pressure, that context persistence is worth more than it sounds.